Comparison of efficacy and safety of novorapid 30R and novomix 30 flexpen in the treatment of type 2 diabetic patients
- VernacularTitle:诺和锐30和诺和灵30R对2型糖尿病的疗效观察
- Author:
Jing XU
- Publication Type:Journal Article
- Keywords:
Novorapid 30R;
NovoMix 30 Flexpen;
Clinical trial;
Diabetes mellitus,type 2
- From:
Journal of Chongqing Medical University
2003;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy and safety of Novoiaped 30 and NovoMix 30 Flexpen in the therapy of type 2 diabetes mellitus(DM). Methods:A multicenter,randomized,and controlled clinical trial of Novorapid 30R and Novomix 30 Flexpen was performed in XinQiao Hospital in Chongqing China. One hundred and fifty patients with type 2 DM received Novorapid 30R therapy and sixty patients received NovoMix 30 Flexpen for 12 weeks respectively. Results:(1)At the end of 12-week treatment,significant improvements in HbA1C and fasting plasma glucose(FPG) levels were shown in both groups, HbA1C decreased 1.08% and 1.01%,and FPG decreased 2.0mmol/L and 2.2mmol/L,in Novorapid 30R and NovoMix 30 Flexpen group respectively(all P0.05). (2)2hpG decreased 3.79mmol/L and 3.05mmol/L,Novorapid 30R was better than Novomix 30 Flexpen,The difference was statistically significant between two groups(P
